CNS Drugs

, Volume 32, Issue 7, pp 637–651 | Cite as

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond

  • Verena Isabell LeussinkEmail author
  • Xavier Montalban
  • Hans-Peter HartungEmail author
Review Article


The oral potassium channel blocker 4-aminopyridine has been used in various neurological conditions for decades. Numerous case reports and studies have supported its clinical efficacy in ameliorating the clinical presentation of certain neurological disorders. However, its short half-life, erratic drug levels, and safety-related dose restrictions limited its use as a self-compounded drug in clinical practice. This changed with the introduction of a prolonged-release formulation, which was successfully tested in patients with multiple sclerosis. It was fully approved by the US FDA in January 2010 but initially received only conditional approval from the European Medicines Agency (EMA) in July 2011. After additional clinical studies, this conditional approval was changed to unrestricted approval in August 2017. This article reviews and discusses these recent studies and places aminopyridines and their clinical utility into the context of a broader spectrum of neurological disorders, where clinical efficacy has been suggested. In 2010, prolonged-release 4-aminopyridine became the first drug specifically licensed to improve walking in patients with multiple sclerosis. About one-third of patients across disease courses benefit from this treatment. In addition, various reports indicate clinical efficacy beyond multiple sclerosis, which may broaden its use in clinical practice.



The authors thank Dr. Peter Göttle for help in creating the figures and Dr. Bernd C. Kieseier for critical review and discussion.

Compliance with Ethical Standards


The authors received no funding for writing this manuscript.

Conflict of interest

VL has received fees for speaking from Biogen, Genzyme, and Novartis and research support from Novartis. XM has received fees for consulting, serving on steering committees, and speaking at symposia from Almirall, Bayer, Biogen, Genzyme, Merck, Roche, Receptos, Sanofi, and Teva. HPH has received, with approval from the Rector of Heinrich-Heine-University, fees for consulting, serving on steering and data monitoring committees, and speaking at scientific symposia from BayerHealthcare, Biogen, Geneuro, Genzyme, Merck, Novartis, Octapharma, Receptos Celgene, Roche, Sanofi, and Teva. None of these were related to the present work.


  1. 1.
    Hauser SL, Johnston SC. 4-Aminopyridine: new life for an old drug. Ann Neurol. 2010;68(1):A8–9. Scholar
  2. 2.
    Giovannini F, Sher E, Webster R, et al. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br J Pharmacol. 2002;136(8):1135–45. Scholar
  3. 3.
    Hayes KC. Fampridine-SR for multiple sclerosis and spinal cord injury. Expert Rev Neurother. 2007;7(5):453–61. Scholar
  4. 4.
    Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology. 1981;31(3):265–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Hayes KC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004;10(4):295–316.CrossRefPubMedGoogle Scholar
  6. 6.
    Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol. 1981;313:301–15.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wu ZZ, Li DP, Chen SR, et al. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem. 2009;284(52):36453–61. Scholar
  8. 8.
    Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain. 2000;123(Pt 1):171–84.CrossRefPubMedGoogle Scholar
  9. 9.
    Schmalhofer WA, Bao J, McManus OB, et al. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry. 2002;41(24):7781–94.CrossRefPubMedGoogle Scholar
  10. 10.
    Varga Z, Csepany T, Papp F, et al. Potassium channel expression in human CD4+ regulatory and naive T cells from healthy subjects and multiple sclerosis patients. Immunol Lett. 2009;124(2):95–101. Scholar
  11. 11.
    Jukkola P, Gu Y, Lovett-Racke AE, et al. Suppression of inflammatory demyelinaton and axon degeneration through inhibiting Kv3 channels. Front Mol Neurosci. 2017;10:344. Scholar
  12. 12.
    Liu Y, Wang X, Li W, et al. A sensitized IGF1 treatment restores corticospinal axon-dependent functions. Neuron. 2017;95(4):817–33 e4. Scholar
  13. 13.
    Bei F, Lee HHC, Liu X, et al. Restoration of visual function by enhancing conduction in regenerated axons. Cell. 2016;164(1–2):219–32. Scholar
  14. 14.
    Bacia A, Wollmann R, Soliven B. K+ channel blockade impairs remyelination in the cuprizone model. Glia. 2004;48(2):156–65. [published Online First: 2004/09/21].CrossRefPubMedGoogle Scholar
  15. 15.
    Bever CT Jr, Leslie J, Camenga DL, et al. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol. 1990;27(4):421–7. Scholar
  16. 16.
    Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1990;27(2):186–92. Scholar
  17. 17.
    Jones RE, Heron JR, Foster DH, et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983;60(3):353–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Stefoski D, Davis FA, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1987;21(1):71–7. Scholar
  19. 19.
    Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991;41(9):1344–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Polman CH, Bertelsmann FW, de Waal R, et al. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol. 1994;51(11):1136–9.CrossRefPubMedGoogle Scholar
  21. 21.
    van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992;32(2):123–30. Scholar
  22. 22.
    Kalla R, Spiegel R, Claassen J, et al. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus. J Neuroophthalmol. 2011;31(4):320–5. Scholar
  23. 23.
    Jensen HB, Ravnborg M, Dalgas U, et al. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7(2):97–113. Scholar
  24. 24.
    Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494–502. Scholar
  25. 25.
    Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732–8. Scholar
  26. 26.
    Burton JM, Bell CM, Walker SE, et al. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology. 2008;71(22):1833–4. Scholar
  27. 27.
    Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med. 2006;30(2):175–7. Scholar
  28. 28.
    Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med. 2011;41(1):51–4. Scholar
  29. 29.
    Goodman AD, Bethoux F, Brown TR, et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two phase 3 clinical trials. Mult Scler. 2015;21(10):1322–31. Scholar
  30. 30.
    Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997;48(4):817–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Hupperts R, Lycke J, Short C, et al. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult Scler. 2016;22(2):212–21. Scholar
  32. 32.
    Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Englishby V, McNeill M, Chang I, Mehta L, Elkins J. Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study. Presented at ECTRIMS 2016, 2016.Google Scholar
  33. 33.
  34. 34.
    Macdonell R, Nagels G, Laplaud DA, et al. Improved patient-reported health impact of multiple sclerosis: the ENABLE study of PR-fampridine. Mult Scler. 2016;22(7):944–54. Scholar
  35. 35.
    Morrow SA, Rosehart H, Johnson AM. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord. 2017;11:4–9. Scholar
  36. 36.
    Broicher SD, Filli L, Geisseler O, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol. 2018;265(5):1016–25. [published Online First: 2018/02/22].CrossRefPubMedGoogle Scholar
  37. 37.
    Horton L, Conger A, Conger D, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology. 2013;80(20):1862–6. Scholar
  38. 38.
    Serra A, Skelly MM, Jacobs JB, et al. Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology. 2014;83(2):192–4. Scholar
  39. 39.
    Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin. 2011;27(7):1415–23. Scholar
  40. 40.
    Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature. 1980;283(5747):570–2.CrossRefPubMedGoogle Scholar
  41. 41.
    Ruck T, Bittner S, Simon OJ, et al. Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci. 2014;337(1–2):18–24. Scholar
  42. 42.
    Filli L, Zorner B, Kapitza S, et al. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. Neurology. 2017;88(9):832–41. Scholar
  43. 43.
    Zorner B, Filli L, Reuter K, et al. Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler. 2016;22(11):1463–75. Scholar
  44. 44.
    Bennett SE. Fampridine: long-term benefits in walking in multiple sclerosis. Neurology. 2017;88(9):818–9. Scholar
  45. 45.
    Rodriguez-Leal FA, Haase R, Thomas K, et al. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? Mult Scler. 2017. [published Online First: 2017/07/26].PubMedCrossRefGoogle Scholar
  46. 46.
    Wagner JN, Glaser M, Brandt T, et al. Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry. 2008;79(6):672–7. Scholar
  47. 47.
    Kalla R, Teufel J, Feil K, et al. Update on the pharmacotherapy of cerebellar and central vestibular disorders. J Neurol. 2016;263(Suppl 1):S24–9. Scholar
  48. 48.
    Claassen J, Spiegel R, Kalla R, et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry. 2013;84(12):1392–9. Scholar
  49. 49.
    Claassen J, Feil K, Bardins S, et al. Dalfampridine in patients with downbeat nystagmus—an observational study. J Neurol. 2013;260(8):1992–6. Scholar
  50. 50.
    Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543–52.CrossRefPubMedGoogle Scholar
  51. 51.
    Jen JC. Hereditary episodic ataxias. Ann NY Acad Sci. 2008;1142:250–3. Scholar
  52. 52.
    Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77(3):269–75. Scholar
  53. 53.
    Schniepp R, Wuehr M, Neuhaeusser M, et al. 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol. 2012;259(11):2491–3. Scholar
  54. 54.
    Yuki N, Hartung HP. Guillain–Barre syndrome. N Engl J Med. 2012;366(24):2294–304. Scholar
  55. 55.
    Goodfellow JA, Willison HJ. Guillain–Barre syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–31. Scholar
  56. 56.
    Lehmann HC, Meyer Zu Horste G, Kieseier BC, et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord. 2009;2(4):261–81. Scholar
  57. 57.
    Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 2014;10(8):435–46. Scholar
  58. 58.
    Bergin PS, Miller DH, Hirsch NP, et al. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol. 1993;34(3):406–9. Scholar
  59. 59.
    Leussink VI, Stettner M, Warnke C, et al. Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. J Peripher Nerv Syst. 2016;21(2):85–7. Scholar
  60. 60.
    Tseng KC, Li H, Clark A, et al. 4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury. EMBO Mol Med. 2016;8(12):1409–20. Scholar
  61. 61.
    Moriguchi K, Miyamoto K, Kusunoki S. 4-Aminopyridine ameliorates experimental autoimmune neuritis in Lewis rats. J Neuroimmunol. 2017;305:72–4. Scholar
  62. 62.
    Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292. Scholar
  63. 63.
    Iaci JF, Parry TJ, Huang Z, et al. Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion. Stroke. 2013;44(7):1942–50. Scholar
  64. 64.
    Simpson DM, Goldenberg J, Kasner S, et al. Dalfampridine in chronic sensorimotor deficits after ischemic stroke: a proof of concept study. J Rehabil Med. 2015;47(10):924–31. Scholar
  65. 65.
    Pena F, Tapia R. Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience. 2000;101(3):547–61.CrossRefPubMedGoogle Scholar
  66. 66.
    Gonzalez OC, Shiri Z, Krishnan GP, et al. Role of KCC2-dependent potassium efflux in 4-aminopyridine-induced epileptiform synchronization. Neurobiol Dis. 2018;109(Pt A):137–47. Scholar
  67. 67.
    Polman CH, Bertelsmann FW, van Loenen AC, et al. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 1994;51(3):292–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother. 2008;42(10):1458–65. Scholar
  69. 69.
    Birnbaum G, Iverson J. Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis. Neurology. 2014;83(18):1610–2. Scholar
  70. 70.
    Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007;13(3):357–68. Scholar
  71. 71.
    De Cauwer H, De Wolf P, Couvreur F, et al. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg. 2009;109(1):40–1.PubMedGoogle Scholar
  72. 72.
    Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71(15):1134–41. Scholar
  73. 73.
    Acorda Therapeutics IAdertpi. 2010.
  74. 74.
    Australian Government DoHaA, Therapeutic Goods Administration. Australian Public Assessment Report for fampridine, 2012.
  75. 75.
  76. 76.
    Fernandez O, Berger T, Hartung HP, et al. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Rev Clin Pharmacol. 2012;5(6):649–65. Scholar
  77. 77.
    Smits RC, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology. 1994;44(9):1701–5.CrossRefPubMedGoogle Scholar
  78. 78.
    Van Diemen HA, Polman CH, Koetsier JC, et al. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol. 1993;16(3):195–204.CrossRefPubMedGoogle Scholar
  79. 79.
    Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 1994;44(6):1054–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Romani A, Bergamaschi R, Candeloro E, et al. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler. 2004;10(4):462–8. Scholar
  81. 81.
    Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, Carlesimo GA, Zibellini G, Caltagirone C. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled,, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7:354–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Neurology, Medical FacultyHeinrich-Heine UniversityDüsseldorfGermany
  2. 2.Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)Hospital Universitario Vall d’HebronBarcelonaSpain
  3. 3.St. Michael’s HospitalUniversity of TorontoTorontoCanada

Personalised recommendations